Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-323-3 | CAS number: 908020-52-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant study, available as unpublished report, no restrictions, fully adequate for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
- Objective of study:
- excretion
- toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The objectives of the study were to evaluate the pharmacokinetic (in blood) and excretion profiles of the test article in rats. Difluoro [1,1,2,2-tetrafluoro-2-(pentafluoro-ethoxy)] ethoxy acetic acid (EEA) in the vehicle, sterile water for injection, was administered intravenously once to 1 pharmacokintic (blood collection) group and 1 excretion group of Crl:CD(SD) rats.
- GLP compliance:
- yes
Test material
- Details on test material:
- - Name of test material (as cited in study report): Difluoro [1,1,2,2-tetrafluoro-2-(pentafluoro-ethoxy)] ethoxy acetic acid (EEA)
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- water
- Duration and frequency of treatment / exposure:
- once
Doses / concentrations
- Remarks:
- Doses / Concentrations:
10 mg/kg bw at a dosage volume of 5 mL/kg
- No. of animals per sex per dose / concentration:
- The pharmacokinetic group consisted of 9 animals/sex and the excretion group consisted of 3 animals/sex
- Control animals:
- no
- Positive control reference chemical:
- none
- Details on dosing and sampling:
- All animals were observed twice daily for mortality and moribundity. Detailed physical examinations were performed at least once during the pre-treatment period. Individual body weights were recorded during acclimation, at pretest initiation, at randomization and on study day 0. Food consumption was recorded during the pretest period only.
For pharmacokinetic assessment, blood samples were collected on wet ice from 3 animals/sex prior to dosing and at approximately 2, 10, 20 and 30 minutes and 1, 3, 5, 7, 24 and 48 hours after dose administration.
For excretion profile, urine samples were collected from 3 animals/sex over the following intervals: 0-6, 6-12 and 12-24 hours post-dosing.
All pharmacokinetic and excretion group animals were euthanized and discarded without further evaluation following the final blood or urine collection.
Serum and urine concentrations of EEA were measured using a validated LCMS/MS method. The concentrations in serum and amounts excreted in urine were used for pharmacokinetic analysis.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- After a single intravenous dose of EEA at 10 mg/kg bw, systemic exposure (AUC0-∞) to EEA for male rats was almost 7-fold higher than for female rats. EEA appeared to remain mostly in the circulation in male rats (apparent volume of distribution about 0.2 L/kg), but to have extensive tissue distribution in female rats (apparent volume of distribution of more than 2.5 L/kg).
- Details on excretion:
- The terminal elimination phase for EEA in serum had a half-life of 9.4 and 5.4 hours for female and male rats, respectively. The half-life for EEA in urine was 1.8 and 3.2 hours, for female and male rats respectively. Nevertheless, the percent of EEA dose eliminated over 24 hours post-dosing in the urine of male rats and female rats was similar (approximately 65%). This can be explained by the lower amounts of EEA available for urinary clearance in the circulation of female rats compared to male rats as suggested by the differences in the apparent volume of distribution.
Metabolite characterisation studies
- Metabolites identified:
- not measured
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies